733
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium

, , , , , & show all
Pages 135-150 | Accepted 18 Jan 2008, Published online: 19 Feb 2010

References

  • Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Annals of Oncology 2007; 18: 1425–1427.
  • The UK Collaborative Group for HIV and STI Surveillance. Testing Times. HIV and Other Sexually Transmitted Infections in the United Kingdom: 2007. Health Protection Agency, Centre for Infections, LondonUK 2007
  • Hulstaert F, Arbyn M, Huybrechts M, et al. Dépistage du cancer du col de l’utérus et recherche du papillomavirus humain (HPV). Health Technology Assessment (HTA). KCE report 38B. Centre fédéral d’expertise des soins de santé (KCE), BrusselsBelgium 2006.
  • Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide.IARC CancerBase No. 5, version 2.0. IARC Press, LyonFrance 2004.
  • Von Krogh G. Management of anogenital warts (condylomata acuminata). European Journal of Dermatology 2001; 11: 598–603
  • Walboomers JMM, Jacobs MV, Manos M, et al. Human papillomavirus: a necessary cause of invasive cervical cancer world-wide. Journal of Pathology 1999; 189: 12–19
  • Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518–527
  • Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247–1249
  • International Agency for Research on Cancer. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10. IARC Press, LyonFrance 2005
  • Arbyn M, Van Oyen H. Cervical cancer screening in Belgium. European Journal of Cancer 2000; 36: 2191–2197
  • Arbyn M, Van Oyen H. Analysis of individual health insurance data pertaining to pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996–2000). Epidemiology, October 2004. Scientific Institute of Public Health, SIPH/EPI Report N 2004–021, BrusselsBelgium
  • Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sexually Transmitted Infections 2004; 80: 255–263
  • Koutsky L. Epidemiology of genital human papillomavirus infection. American Journal of Medicine 1997; 102: 3–8
  • Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. Journal of Infectious Diseases 2007; 196: 1447–1454
  • McMillan A. The management of difficult anogenital warts. Sexually Transmitted Diseases 1999; 75: 192–194
  • Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24((Suppl 3))S35–S41.
  • Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Current Medical Research and Opinion 2006; 22: 663–670.
  • Arveux P, Benard S, Bouee S, et al. Invasive cervical cancer treatment costs in France. Bulletin du Cancer 2007; 94: 219–224
  • Bergeron C, Breugelmans JG, Bouée S, et al. [Cervical cancer screening and associated treatment costs in France.]. Gynécologie, Obstétrique & Fertilité 2006; 34: 1036–1042, [in French]
  • Monsonégo J, Breugelmans JG, Bouée S, et al. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynécologie, Obstétrique & Fertilité 2007; 35: 107–113, [in French].
  • National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at: http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm [accessed July 2007].
  • Pirson M, Dramaix M, Leclercq P, et al. Analysis of cost outliers within APR-DRGs in a Belgian general hospital: two complementary approaches. Health Policy 2006; 76: 13–25
  • Analyse économique des coûts du cancer en France: impact sur la qualité de vie, prévention, dépistage, soins, recherche. «Etudes et expertises» éditée par l’Institut National du Cancer. Mars 2007
  • National Institute for Statistics. Statistics Belgium. Available at: http://www.statbel.fgov.be [accessed July 2007]
  • National Institute for Statistics. Available at: http://statbel.fgov.be/downloads/lfs1004-2004_fr.xls [accessed July 2007]
  • National Institute for Health Insurance (INAMI/RIZIV). Available at: http://www.riziv.be [accessed July 2007]
  • Castellsague X, De San José S, Aguado T, et al. HPV and cervical cancer in the world, 2007 report. Vaccine 2007; 25: C27–C219
  • De Schrijver K. Epidemiologisch bulletin van de vlaamse gemeenschap, De epidemiologie van seksueel overdraagbare aandoeningen in belgië. NR 45 2003/3
  • Belgian Cancer Registry Foundation. Available at: http://www.kankerregister.be/ [accessed December 2007]
  • Available at: http://www.onssrszlss.fgov.be/Onssrsz/FR/Statistics/Brochures/Green/xls/rrn_2007_1_fr.xls [accessed July 2007]
  • The National Centre for Screening Monitoring Fourth Report. Rivista dell’Associazione italiana di epidemiologia. Anno 30 (1) 2006 Supplemento 3
  • Direction générale statistique et information économique. Population et ménages, Population totale et belge. 2004
  • Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. European Journal of Cancer 1998; 34: 1889–1893.
  • Thiry N, Lambert ML, Cleemput I, et al. Vaccination HPV pour la prévention du cancer du col de l’utérus en Belgique: Health Technology Assessment. KCE report 64B. Centre fédéral d’expertise des soins de santé (KCE), BrusselsBelgium 2007
  • Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007; 356: 1928–1943.
  • The FUTURE. II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 2007; 356: 1915–1927
  • Bergeron C, Largeron N, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. International Journal of Technology Assessment in Health Care 2008; 24: 10–19
  • Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases 2007; 13: 28–41

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.